NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Co-Founder and CSO Develops Method to Identify Women Who Will Benefit from Tamoxifen Therapy for Breast Cancer
IRVINE, CA and AMSTERDAM, July 31, 2014 – Innovative research by Rene Bernards, Ph.D., the co-founder of Agendia, Inc., has identified a gene signature that has potential to identify which patients will benefit from tamoxifen Read More
Agendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer
IRVINE, CA, AMSTERDAM and Rye Brook, N.Y., July 16, 2014 – Agendia, a leading molecular diagnostics company, and CBLPath, Inc., a leading pathology services provider, today announced they have agreed to collaborate in providing molecular Read More
Value of Breast Cancer Molecular Subtyping Documented by Independent Study Comparing Genomic Tests at ASCO 2014 Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, June 10, 2014 – There are substantial differences between the results provided by Agendia’s next-generation breast cancer tests and more limited results from the first-generation, 21-gene assay, according to Read More







